Welcome to the e-CCO Library!

P612: Exclusive enteral nutrition in adults with active Crohn's disease is associated with decreased disease activity
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Pfeffer-Gik T., Yanai H., Godny L., Ron Y., Maharshak N., Dotan I.

Created: Wednesday, 20 February 2019, 10:36 AM
P612: Lack of seroconversion following COVID-19 vaccination, but not treatment, is an independent risk factor for breakthrough SARS-CoV-2 infection in patients with inflammatory bowel disease: data from ESCAPE - an IG-IBD Study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Macaluso, F.S.(1)*;Principi, M.(2);Facciotti, F.(3);Contaldo, A.(4);Todeschini, A.(5);Bezzio, C.(6);Saibeni, S.(6);Castiglione, F.(7);Nardone, O.M.(7);Spagnuolo, R.(8);Fantini, M.C.(9);Riguccio, G.(10);Conforti, F.S.(11);Caprioli, F.A.(11);Viganò, C.(12);Felice, C.(13);Fiorino, G.(14);Correale, C.(15);Bodini, G.(16);Milla, M.(17);Scardino, G.(18);Vernero, M.(19);Desideri, F.(20);Bossa, F.(21);Guerra, M.(21);Ventimiglia, M.(22);Mannino, M.(1);Rizzo, G.(23);Orlando, A.(1);
Created: Friday, 14 July 2023, 11:05 AM
P612: Long-term outcomes of treatment intervention according to the severity of small bowel capsule endoscopy findings in patients with Crohn’s disease: A Japanese single-centre cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Nasuno*1, H. Tanaka1, K. Sugiyama1, M. Miyakawa1, S. Motoya1

Created: Friday, 22 February 2019, 9:41 AM
P612: Lower incidence of COVID-19 in patients with Inflammatory Bowel Diseases treated with non-gut-selective biologic therapy: an observational multicentre study.
Year: 2021
Source: ECCO'21 Virtual
Authors: Ferretti, F.(1);Monico, M.C.(1);Carvalhas Gabrielli, A.M.(1);Carmagnola, S.(1);Bezzio, C.(2);Saibeni, S.(2);Bosani, M.(3);Caprioli, F.(4);Mazza, S.(4);Casini, V.(5);Cortelezzi, C.(6);Parravicini, M.(6);Cassinotti, A.(6);Cosimo, P.(7);Indriolo, A.(7);Di Sabatino, A.(8);Lenti, M.V.(8);Pastorelli, L.(9);Conforti, F.(9);Ricci, C.(10);Sarzi-Puttini, P.(11);Vecchi, M.(4);Maconi, G.(1);Ardizzone, S.(11);
Created: Wednesday, 2 June 2021, 4:12 PM
P612: Mirikizumab Pharmacokinetics and Exposure - Efficacy Relationships in Patients with Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Friedrich, S.(1);Chua, L.(1);Tuttle, J.L.(2);Feagan, B.G.(3);Sandborn, W.J.(4);
Created: Friday, 11 February 2022, 3:56 PM
P613 Use of adalimumab biosimilar ABP 501 in Crohn’s disease: A real-life experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D.G. Ribaldone1, M. Vernero2, R. Pellicano3, M. Morino1, G.M. Saracco4, M. Astegiano3

Created: Thursday, 30 January 2020, 10:12 AM
P613: Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn’s disease patients failure to TNF inhibitors.
Year: 2022
Source: ECCO'22
Authors: Onali, S.(1);Pugliese, D.(2);Caprioli, F.A.(3);Orlando, A.(4);Biancone, L.(5);Nardone, O.M.(6);Imperatore, N.(7);Fiorino, G.(8);Cappello, M.(9);Viola, A.(10);Principi, M.B.(11);Bezzio, C.(12);Aratari, A.(13);Carparelli, S.(14);Mazzuoli, S.(15);Manguso, F.(7);Grossi, L.(16);Bodini, G.(17);Ribaldone, D.(18);Mocci, G.(19);Minerba, L.(20);Favale, A.(21);Grova, M.(22);Scucchi, L.(23);Segato, S.(24);Fries, W.(25);Castiglione, F.(26);Armuzzi, A.(2);Fantini, M.C.(27);
Created: Friday, 11 February 2022, 3:56 PM
P613: Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-alpha inhibitors and conventional immunosuppressants
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Macaluso F.S.*1, Maida M.2, Renna S.1, Orlando E.1, Affronti M.1, Sapienza C.1, Dimarco M.1, Orlando R.1, Rizzuto G.1, Cottone M.1, Orlando A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P613: Predictors of treatment persistence in ulcerative colitis patients treated with golimumab: A multicentre cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Biscaglia1, E. Savarino2, A. Variola3, F. Furfaro4, C. Ferracane5, G. Rizzati6, F. Scaldaferri6, G. Mocci7, A. Buda8, A. Privitera5, A. Geccherle3, G. Fiorino9,10*

Created: Thursday, 21 February 2019, 9:14 AM
P613: Social Media Analytics for Inflammatory Bowel Disease – What Are We Missing?
Year: 2021
Source: ECCO'21 Virtual
Authors: Kumar, L.(1);Kiely, L.(1);O'Riordan, A.(1);Barry, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P613: Switch from intravenous to subcutaneous maintenance infliximab in real world IBD cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Mcgrory, L.(1)*;Goess, C.(1);Lynch, K.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P613: Tacrolimus as rescue therapy for steroid-dependent/steroid refractory ulcerative colitis: experience from tertiary referral centre
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Sud*1, A. S. Puri1

Created: Friday, 22 February 2019, 9:41 AM
P614 Micro-fragmented autologous adipose tissue injection for fistula-in-ano (MAATIFA) in patients with Crohn’s disease: A prospective observational study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Sturiale1, B. Fabiani1, D. Cafaro1, C. Menconi1, F. Celedon Porzio1, M. Franceschi2, G. Naldini1

Created: Thursday, 30 January 2020, 10:12 AM
P614: A strategy to solve complexity of physician diagnosis using a mixture of Patient Reports and Provider Reports: A Case Study of Crohn’s Disease Phenotypes
Year: 2021
Source: ECCO'21 Virtual
Authors: Zhang, L.(1);Fan, Y.(2);Thompson, J.(3);Bohn, R.(4);Negar, O.(4);Brodovicz, K.(2);Parakkal, D.(5);
Created: Wednesday, 2 June 2021, 4:12 PM
P614: Anti-TNFs more frequently stopped due to loss of response in British Asians with Crohn's disease: a single centre retrospective analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gadhok R.1, Gordon H.*1, Sebepos-Rogers G.1, Baillie S.1, Akbar S.1, Ahmad O.F.1, Cooper B.1,2, Lindsay J.O.1,3

Created: Wednesday, 20 February 2019, 10:36 AM
P614: Pregnancy outcomes in women with IBD treated with biosimilar infliximab
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Kolar1*, D. Duricova1,2, M. Bortlik1,3, M. Lukas1, V. Hruba1, N. Machkova1, K. Malickova1, M. Lukas1,4

Created: Thursday, 21 February 2019, 9:14 AM
P614: Proactive infliximab is superior to either conventional infliximab and vedolizumab in Inflammatory Bowel Disease
Year: 2022
Source: ECCO'22
Authors: Rodrigues, I.(1);Serrazina, J.(1);Botto, I.(1);Fernandes, S.(1);Bernardo, S.(1);Gonçalves, A.R.(1);Moura Santos, P.(1);Valente, A.(1);Correia, L.(1);Tato Marinho, R.(1);
Created: Friday, 11 February 2022, 3:56 PM
P614: Reduction of bowel wall thickness and doppler signals as early as 36 hours predicts corticosteroid response in a multi-centre prospective cohort of Acute Severe Ulcerative Colitis: USUC Study including the GENIUS cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: An, Y.K.(1)*;Fernandes, R.(1);Lindsay, N.(2);Khoo, E.(1);Pham, H.(2);Wong, K.F.(2);Thin, L.(3);Goodsall, T.(4);Bryant, R.V.(4);Wright, E.(5);Smith, R.(6);Friedman, A.(6);Begun, J.(1);
Created: Friday, 14 July 2023, 11:05 AM
P614: The utility as a biomarker of faecal calprotectin for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis treatment in patients with ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Ueno*1, Y. Murakami1, T. Iwama1, T. Sasaki1, T. Kunogi1, K. Takahashi1, K. Tanaka2, K. Ando1, S. Kashima1, Y. Inaba3, K. Moriichi1, H. Tanabe1, M. Taruishi3, M. Fujiya1, T. Okumura1

Created: Friday, 22 February 2019, 9:41 AM